BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180527
DTEND;VALUE=DATE:20180629
DTSTAMP:20260730T145649
CREATED:20180527T131832Z
LAST-MODIFIED:20180527T132216Z
UID:20262-1527379200-1530230399@ces.b2sg.org
SUMMARY:Associate Research Scientist
DESCRIPTION:Apply On Company Site\n\n\n\n\nColumbia University invites applications for a molecular biologist appointment in the Department of Pathology and Cell Biology at the Columbia University Medical Center in Dr. Kevin Gardner’s Lab. Positions are available to study basic mechanisms of epigenetic gene regulation and transcriptional control in breast cancer. The lab has an integrated focus on fundamental mechanisms of chromatin-based transcriptional control\, including basic mechanisms of epigenetic regulation and enhancer function (Proc Natl Acad Sci U S A. 2009 Nov 17;106(46): 19286-91; Nat Struct Mol Biol. 2010 Dec;17(12): 1406-13; Nat Commun. 2012 Jan 17;3:633; Nat Commun. 2013;4:1449). New initiatives include the application of these methods and approaches to translational research to improve the diagnosis\, treatment and prevention of breast cancer. Central themes are understanding the role of transcriptional cross-talk and intersections receptor-mediated signaling pathways in the control of enhancer-mediated influence on gene expression. A major goal in the lab is the development omic perspectives that integrate next-generation sequencing with genomics\, transcriptomics\, epigenomics\, proteomics and metabolomics. The projects will be supported by access to an established diverse cohort of breast cancer patient samples with deep next generation molecular genomic characterization for both gene and pathway discovery and translation application in diagnosis\, treatment\, and prevention.  \nMinimum Degree Required:\n Ph.D. / M.D. or both  \nMinimum Qualifications:\n All applicants MUST meet these minimum qualifications to be considered for the position.  \nCandidate must have background in one or more our current research specialties: Cancer Biology\, Neurodegenerative diseases\, Cellular and molecular neurobiology\, Cell motility\, Cytoskeleton and intracellular trafficking\, Virology\, Molecular Biology\, Neuronal stem cells and Anatomic or Clinical pathology.  \nPreferred Qualifications:\n Ph.D. or M.D. equivalent in areas molecular biology or related field. Expertise in the construction sequencing libraries for various genomic analytical platforms including RNA-seq\, Exome-sequencing\, and ChIP-seq is required. Experience in the performance and analysis of ChIP-seq is required. Familiarity with CRISPR/Cas9 technology and ATTAC-seq analysis is highly desirable. An understanding of bioinformatic approaches and technologies in manipulating and interpreting deep sequencing data would be a significant advantage. We are looking for individuals with a strong desire to work on fundamental research questions in cancer and chromatin biology. Those candidates with a proven research experience and a history of an ability to independently drive a project forward in an interactive environment\, with willingness to provide mentorship to junior lab members\, would be highly competitive. 
URL:https://ces.b2sg.org/event/cu-27may18/
LOCATION:Columbia University Medical Center\, 630 W 168th St\, New York\, NY\, 10032\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/11/Columbia-University-Medical-Center.jpg
END:VEVENT
END:VCALENDAR